Alaunos Therapeutics Reports Q2 2025 Financial Results, Shifts Focus to Obesity Therapeutics

Alaunos Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $1.1 million for the three months ended June 30, compared to a loss of $1.1 million for the same period in 2024. The company did not generate any revenue during the quarter, a decline from $4,000 in the previous year. For the first half of 2025, Alaunos recorded a net loss of $2.1 million, down from $2.8 million in the first half of 2024. The accumulated deficit as of June 30, 2025, stood at approximately $922.6 million, reflecting the company's ongoing challenges in achieving profitability.

In terms of operational changes, Alaunos has shifted its focus from oncology to developing small molecule therapeutics for obesity and metabolic disorders. This strategic pivot follows the wind-down of its TCR-T Library Phase 1/2 Trial, which was announced in August 2023. The company has since reduced its workforce significantly and is actively exploring strategic alternatives, including potential mergers or partnerships. As part of its restructuring, Alaunos has also terminated several key licensing agreements, including its exclusive license with Precigen.

Financially, Alaunos has made strides in capital raising, securing $1.9 million in net proceeds from a registered direct offering in June 2025, which included the sale of common stock and pre-funded warrants. Additionally, the company raised $500,000 from the sale of Series A-1 preferred stock and $850,000 from Series A-2 preferred stock. As of June 30, 2025, Alaunos reported $2.9 million in cash and cash equivalents, an increase from $1.1 million at the end of 2024, indicating improved liquidity.

The company’s operational metrics reflect its ongoing transition. Research and development expenses for the first half of 2025 increased to $531,000 from $306,000 in the prior year, primarily due to costs associated with regulatory submissions and consulting fees for the obesity program. General and administrative expenses decreased significantly, from $2.6 million in the first half of 2024 to $1.6 million in 2025, attributed to reduced employee-related costs and operational downsizing.

Looking ahead, Alaunos anticipates that its current cash resources will be sufficient to fund operations into the first quarter of 2026. However, the company has expressed substantial doubt regarding its ability to continue as a going concern without securing additional financing. The management is actively seeking opportunities to raise capital to support its new strategic direction and ongoing development efforts in obesity therapeutics.